Apogee Therapeutics, Inc. is a clinical stage biotechnology company. It offers treatment of atopic dermatitis (AD), ashma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded by Andrew Gottesdiener and Nimish P. Shah in 2022 and is headquartered in Waltham, MA.